JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sarkar, S. D.
Right arrow Articles by Palestro, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sarkar, S. D.
Right arrow Articles by Palestro, C. J.
Journal of Nuclear Medicine Vol. 43 No. 5 632-634
© 2002 by Society of Nuclear Medicine


Brief Communications

Comparison of 123I and 131I for Whole-Body Imaging in Thyroid Cancer

Salil D. Sarkar, MD1, Tomy P. Kalapparambath, MD1 and Christopher J. Palestro, MD1

1 Division of Nuclear Medicine, Department of Radiology, Long Island Jewish Medical Center, New Hyde Park, New York

ABSTRACT

We compared the diagnostic sensitivities of 123I and 131I whole-body imaging in differentiated thyroid cancer. Methods: Twelve thyroidectomized patients (3 previously treated with 131I) were studied. After a period of thyroid hormone withdrawal, whole-body imaging was performed approximately 24 and 72–96 h after administration of 74–185 MBq (2–5 mCi) 123I and 111–185 MBq (3–5 mCi) 131I, respectively. Results: Both 123I and 131I revealed residual thyroid tissue, present in 9 patients. 131I detected metastases in 5 studies of 4 patients. In 4 of 5 studies, 123I missed metastases shown by 131I in 8 body regions including the neck, mediastinum, lungs, and bone and detected 3 other sites of metastasis only in retrospect. No lesion was better seen with 123I than with 131I. Conclusion: Although 123I is adequate for imaging residual thyroid tissue, it appears to be less sensitive than 131I for imaging thyroid cancer metastases.

Key Words: 123I • 131I • thyroid cancer




This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
B Jarzab, D Handkiewicz-Junak, and J Wloch
Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review
Endocr. Relat. Cancer, December 1, 2005; 12(4): 773 - 803.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
S. K. Gerard and H. Q. Dam
Stunning with 131I Diagnostic Whole-Body Imaging of Patients with Thyroid Cancer * Dr Dam responds:
Radiology, March 1, 2005; 234(3): 972 - 974.
[Full Text] [PDF]


Home page
JNMHome page
S. K. Gerard, S. Mandel, S. D. Sarkar, C. J. Palestro, and T. P. Kalapparambath
131I Versus 123I for Whole-Body Scanning
J. Nucl. Med., July 1, 2003; 44(7): 1194 - 1195.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2002 by the Society of Nuclear Medicine.